TARGETING, DOSIMETRY, AND RADIOIMMUNOTHERAPY OF B-CELL LYMPHOMAS WITH IODINE-131-LABELED LL2 MONOCLONAL-ANTIBODY

被引:212
作者
GOLDENBERG, DM
HOROWITZ, JA
SHARKEY, RM
HALL, TC
MURTHY, S
GOLDENBERG, H
LEE, RE
STEIN, R
SIEGEL, JA
IZON, DO
BURGER, K
SWAYNE, LC
BELISLE, E
HANSEN, HJ
PINSKY, CM
机构
[1] IMMUNOMED INC, NEWARK, NJ USA
[2] UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, DEPT RADIOL, NEWARK, NJ 07103 USA
[3] MORRISTOWN MEM HOSP, DEPT RADIOL, MORRISTOWN, NJ 07960 USA
[4] IMMUNOMED INC, WARREN, NJ USA
关键词
D O I
10.1200/JCO.1991.9.4.548
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sixteen patients with non-Hodgkin's lymphoma were infused with 6.2 to 58.2 mCi (0.2 to 3.9 mg) doses of radioactive iodine (131I)-labeled LL2 immunoglobulin G (IgG) or F(ab')2, in order to study antibody distribution, pharmacokinetics, dosimetry, toxicity, tumor targeting, and therapy. LL2 is a murine IgG2a monoclonal antibody (MAb) reactive with B cells and non-Hodgkin's B-cell lymphoma. In a series of five assessable therapy patients, doses as small as 30 mCi 131I-LL2 IgG or F(ab')2 resulted in tumor responses (two partial remissions, two mixed and minor responses, and one no response), while one patient receiving diagnostic doses as low as 6.2 mCi showed a partial remission for 1 year and a complete remission after a second low radiation dose. No acute toxicities were noted, and only myelotoxicity accompanied therapeutic doses, with grade IV marrow toxicity seen in three of seven patients receiving total doses of about 50 mCi. Dosimetry calculations showed spleen and tumor dose rates of about 4.6 cGy/mCi, which was three to four times the dose to other organs. Despite the administration of relatively low doses of LL2 (0.2 to 3.9 mg), 82% of 60 known extrasplenic lymphoma sites were imaged. Serum clearance showed an average distribution half-life (T1/2) of 2.1 hours and an elimination T1/2 of 32.0 hours. The average total-body clearance T1/2 was 43 to 45 hours. LL2′s antigenic target does not appear to be shed in high amounts into the circulation. Three of eight patients having at least two injections showed a human antimouse antibody response. These patients may have been presensitized to animal protein. An interesting observation in this study was the marked drop in circulating B lymphocytes after the administration of radioiodinated LL2 or anticarcinoembryonic antigen MAbs, suggesting that this is a nonspecific radiation effect and not necessarily related to the binding of MAb to normal B cells. © 1991 by American Society of Clinical Oncology.
引用
收藏
页码:548 / 564
页数:17
相关论文
共 75 条
  • [71] WEADOCK KS, 1990, J NUCL MED, V31, P508
  • [72] RADIOBIOLOGICAL COMPARISON OF EXTERNAL BEAM IRRADIATION AND RADIOIMMUNOTHERAPY IN RENAL-CELL CARCINOMA XENOGRAFTS
    WESSELS, BW
    VESSELLA, RL
    PALME, DF
    BERKOPEC, JM
    SMITH, GK
    BRADLEY, EW
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 17 (06): : 1257 - 1263
  • [73] SEROTHERAPY OF MALIGNANT DISEASE
    WRIGHT, PW
    HELLSTROM, KE
    HELLSTROM, IE
    BERNSTEIN, ID
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 1976, 60 (03) : 607 - 622
  • [74] ABSOLUTE QUANTITATION OF RADIOACTIVITY USING THE BUILDUP FACTOR
    WU, RK
    SIEGEL, JA
    [J]. MEDICAL PHYSICS, 1984, 11 (02) : 189 - 192
  • [75] ZIMMER AM, 1988, ANTIBODY IMMUNOCONJ, V1, P291